Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
21 hedge funds and large institutions have $2.1M invested in Titan Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
13% less funds holding
Funds holding: 24 → 21 (-3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
41% less capital invested
Capital invested by funds: $3.55M → $2.1M (-$1.45M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$193K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$24.9K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$12.4K |
| 4 |
BlackRock
New York
|
+$6.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MERSOM
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
|
-$531K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$168K |
| 3 |
Millennium Management
New York
|
-$162K |
| 4 |
D.E. Shaw & Co
New York
|
-$63K |
| 5 |
GS
Gagnon Securities
New York
|
-$61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
27
BNP Paribas Financial Markets
Paris,
France
| $3 | – | – | – |
|
|
MERSOM
28
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
| – | -$531K | -84 | Closed |
|
|
29
D.E. Shaw & Co
New York
| – | -$63K | -10 | Closed |
|
|
GS
30
Gagnon Securities
New York
| – | -$61K | -10 | Closed |
|
31
Dimensional Fund Advisors
Austin,
Texas
| – | -$31K | -5 | Closed |
|
|
RJFSA
32
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$27K | -4 | Closed |
|
33
UBS Group
Zurich,
Switzerland
| – | -$6.22K | -1 | Closed |
|
TTNP Hedge Fund Activity: Q4 2017 in Review
21 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2017, worth a combined $2.1M — down 41% from $3.55M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TTNP and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $193K. The largest seller was Municipal Employees' Retirement System of Michigan, exiting entirely with an estimated $531K sold.
- 21 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2017, down from 24 in Q3 2017.
- Funds reported $2.1M of Titan Pharmaceuticals stock for Q4 2017, down 41% quarter-over-quarter.
- 3 funds opened new Titan Pharmaceuticals positions in Q4 2017 and 6 closed out, a net change of -3 holders.
- The largest Titan Pharmaceuticals buyer in Q4 2017 was Renaissance Technologies, an estimated $193K added.
- The largest Titan Pharmaceuticals seller in Q4 2017 was Municipal Employees' Retirement System of Michigan, an estimated $531K sold.
Based on aggregated 13F filings for Q4 2017.